C
Chen Wang
Researcher at Mayo Clinic
Publications - 198
Citations - 15466
Chen Wang is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Serous fluid. The author has an hindex of 33, co-authored 159 publications receiving 11490 citations. Previous affiliations of Chen Wang include Shanghai Jiao Tong University & University of Science and Technology of China.
Papers
More filters
Journal ArticleDOI
Target-enrichment sequencing and copy number evaluation in inherited polyneuropathy
Wei Wang,Chen Wang,D. Brian Dawson,Erik C. Thorland,Patrick A. Lundquist,Bruce W. Eckloff,Yanhong Wu,Saurabh Baheti,Jared M. Evans,Steven S. Scherer,Peter James Dyck,Christopher J. Klein +11 more
TL;DR: In this paper, a copy number variation algorithm was applied on NGS data, and validated the identified copy number mutations using CytoScan (Affymetrix) to assess the efficiency of target-enhancement next-generation sequencing (NGS) with copy number assessment in inherited neuropathy diagnosis.
Journal ArticleDOI
TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer
Jeremy Chien,Hugues Sicotte,Jian-Bing Fan,Sean Humphray,Julie M. Cunningham,Kimberly R. Kalli,Ann L. Oberg,Steven N. Hart,Ying Li,Jaime I. Davila,Saurabh Baheti,Chen Wang,Sabine Dietmann,Elizabeth J. Atkinson,Yan W. Asmann,Debra A. Bell,Takayo Ota,Yaman Tarabishy,Rui Kuang,Marina Bibikova,R. Keira Cheetham,Russell J. Grocock,Elizabeth M. Swisher,John F. Peden,David Bentley,Jean Pierre A. Kocher,Scott H. Kaufmann,Lynn C. Hartmann,Viji Shridhar,Ellen L. Goode +29 more
TL;DR: Evidence that structural variants (SV) cluster in HGSOC, but are absent in one ultramutated tumor, providing insights into the pathogenesis of low stage H GSOC is found, and deleterious TP53 mutations are the earliest events.
Journal ArticleDOI
PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data
Chen Wang,Jared M. Evans,Aditya Bhagwate,Naresh Prodduturi,Vivekananda Sarangi,Mridu Middha,Hugues Sicotte,Peter T. Vedell,Steven N. Hart,Gavin R. Oliver,Jean Pierre A. Kocher,Matthew J. Maurer,Anne J. Novak,Susan L. Slager,James R. Cerhan,Yan W. Asmann +15 more
TL;DR: A novel method named PatternCNV, which accounts for the read coverage variations between exons while leveraging the consistencies of this variability across different samples, and incorporates multiple QC measures designed to identify outlier samples and batch effects.
Journal ArticleDOI
The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins
Zheng Li,Zheng Li,Matthew S. Block,Robert A. Vierkant,Zachary C. Fogarty,Stacey J. Winham,Daniel W. Visscher,Kimberly R. Kalli,Chen Wang,Ellen L. Goode +9 more
TL;DR: Results suggest that activation of TLR4/MyD88/NF-κB signaling by endogenous ligands may contribute to an inflammatory microenvironment that drives a more aggressive phenotype with poorer clinical outcome in EOC patients.
Journal ArticleDOI
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Aline Talhouk,Joshy George,Chen Wang,Timothy Budden,Timothy Budden,Tuan Zea Tan,Derek S. Chiu,Stefan Kommoss,Huei San Leong,Stephanie Chen,Maria P. Intermaggio,Blake Gilks,Tayyebeh M. Nazeran,Mila Volchek,Wafaa Elatre,Rex C. Bentley,Janine Senz,Amy Lum,Veronica Chow,Hanwei Sudderuddin,Robertson Mackenzie,Samuel C Y Leong,Geyi Liu,Dustin Johnson,Billy Chen,Jennifer Alsop,Susana Banerjee,Sabine Behrens,Clara Bodelon,Alison Brand,Louise A. Brinton,Michael E. Carney,Yoke-Eng Chiew,Yoke-Eng Chiew,Kara L. Cushing-Haugen,Cezary Cybulski,Darren Ennis,Darren Ennis,Sian Fereday,Sian Fereday,Renée T. Fortner,Jesús García-Donas,Aleksandra Gentry-Maharaj,Rosalind Glasspool,Teodora Goranova,Casey S. Greene,Paul Haluska,Holly R. Harris,Holly R. Harris,Joy Hendley,Joy Hendley,Brenda Y. Hernandez,Esther Herpel,Mercedes Jimenez-Linan,Chloe Karpinskyj,Scott H. Kaufmann,Gary L. Keeney,Catherine J. Kennedy,Catherine J. Kennedy,Martin Köbel,Jennifer M Koziak,Melissa C. Larson,Jenny Lester,Jenny Lester,Liz-Anne Lewsley,Jolanta Lissowska,Jan Lubinski,Hugh Luk,Geoff Macintyre,Sven Mahner,Iain A. McNeish,Iain A. McNeish,Janusz Menkiszak,Nikilyn Nevins,Ana Osorio,Oleg Oszurek,José Palacios,Samantha Hinsley,Celeste Leigh Pearce,Celeste Leigh Pearce,Malcolm C. Pike,Malcolm C. Pike,Anna M. Piskorz,Isabelle Ray-Coquard,Valerie Rhenius,Cristina Rodríguez-Antona,Raghwa Sharma,Raghwa Sharma,Mark E. Sherman,D.G.H. de Silva,Naveena Singh,Peter Sinn,Dennis J. Slamon,Honglin Song,Helen Steed,Euan A. Stronach,Pamela J. Thompson,A. Toloczko,Britton Trabert,Nadia Traficante,Nadia Traficante,Chiu-Chen Tseng,Martin Widschwendter,Lynne R. Wilkens,Stacey J. Winham,Boris Winterhoff,Alicia Beeghly-Fadiel,Javier Benitez,Andrew Berchuck,James D. Brenton,Robert S. Brown,Jenny Chang-Claude,Jenny Chang-Claude,Georgia Chenevix-Trench,Anna deFazio,Anna deFazio,Peter A. Fasching,Peter A. Fasching,María Josefa Mosteiro García,Simon A. Gayther,Marc T. Goodman,Jacek Gronwald,Michelle J. Henderson,Beth Y. Karlan,Beth Y. Karlan,Linda E. Kelemen,Usha Menon,Sandra Orsulic,Sandra Orsulic,Paul D.P. Pharoah,Nicolas Wentzensen,Anna H. Wu,Joellen M. Schildkraut,Mary Anne Rossing,Mary Anne Rossing,Gottfried E. Konecny,David G. Huntsman,Ruby Yun-Ju Huang,Ruby Yun-Ju Huang,Ellen L. Goode,Susan J. Ramus,Jennifer A. Doherty,David D.L. Bowtell,David D.L. Bowtell,Michael S. Anglesio +144 more
TL;DR: A fully defined and locked-down clinical grade PrOTYPE assay will enable trial design with molecular subtype stratification and allow for objective assessment of the predictive value of HGSOC molecular subtypes in precision medicine applications.